CareDx Receives Medicare Reimbursement Pricing for AlloSure Heart

Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) announced a significant development regarding its AlloSure Heart test, which has received final reimbursement pricing of $2,753 from Palmetto MolDx. This donor-derived cell-free DNA test detects organ rejection in heart transplant patients and is covered by Medicare when paired with AlloMap Heart gene expression profiling. The combination, known as HeartCare, is a non-invasive solution aimed at enhancing patient management. CEO Reg Seeto emphasized that this milestone will improve heart transplant patient care accessibility.

Positive

• Received final reimbursement pricing of $2,753 for AlloSure Heart.
• AlloSure Heart is now covered by Medicare when used with AlloMap Heart.
• HeartCare offers a non-invasive solution for managing heart transplant patients.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it has received final reimbursement pricing of $2,753 from Palmetto MolDx for AlloSure Heart.

AlloSure Heart is a donor-derived cell-free DNA (dd-cfDNA) test which can identify underlying cell injury leading to organ rejection, and is covered by Medicare when used in conjunction with AlloMap Heart gene expression profiling. HeartCare, the combination of AlloSure Heart and AlloMap Heart, provides a multi-modality and non-invasive solution for managing the care of transplant patients.

“We are pleased to reach this milestone for AlloSure Heart which broadens accessibility to HeartCare, and improves management of heart transplant patients,” said Reg Seeto, President and Chief Executive Officer. “This non-invasive, multi-modality solution represents the latest innovation in precision medicine. HeartCare will help redefine the way clinicians manage the care of transplant patients.”

About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com

Investor Relations
Greg Chodaczek
347-620-7010
investor@caredx.com 

 

FAQ

What is AlloSure Heart and its significance for CareDx (CDNA)?

AlloSure Heart is a donor-derived cell-free DNA test that helps identify organ rejection in heart transplant patients. It is significant for CareDx as it is now reimbursed at $2,753, increasing accessibility and enhancing management of transplant patients.

When did CareDx announce the reimbursement for AlloSure Heart?

CareDx announced the reimbursement for AlloSure Heart on November 17, 2020.

What is the Medicare coverage for AlloSure Heart related to CareDx (CDNA)?

Medicare covers AlloSure Heart when used in conjunction with AlloMap Heart gene expression profiling, allowing for broader access to this critical test for heart transplant patients.

How does HeartCare improve patient management according to CareDx (CDNA)?

HeartCare combines AlloSure Heart and AlloMap Heart, providing a non-invasive, multi-modality solution that enhances the management of heart transplant patients by monitoring organ health more effectively.